CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 86 enrolled
Drug / intervention
Pegylated Liposomal Doxorubicin + SL-172154 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05483933
NCT05483933Phase 1Completed
CompareCT.gov

An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered With Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects With Platinum-Resistant Ovarian Cancers

Shattuck Labs, Inc.·interventional·Posted Aug 2, 2022·Updated Dec 23, 2025

In Brief

A Phase 1 clinical trial evaluating Pegylated Liposomal Doxorubicin + SL-172154 and Mirvetuximab + SL-172154 for Platinum-resistant Ovarian Cancer and 6 related conditions. Completed, enrolled 86 participants across 21 sites in 4 countries.

Detailed Summary

SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 patients will be enrolled in this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlatinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma
CountriesCanada, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedAug 2, 2022
Enrollment StartAug 18, 2022
Primary CompletionFeb 7, 2025
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 3.9 years ago

Interventions

Pegylated Liposomal Doxorubicin + SL-172154drug

The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.

Mirvetuximab + SL-172154drug

The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.